Authors: CURE H VANPRAAGH I CHARRIER S KWIATKOWSKI F FERRIERE JP CHOLLET P

Citation: H. Cure et al., PHASE-I OF DOXORUBICIN AND IFOSFAMIDE ASSOCIATION FOR FIRST LINE ADVANCED BREAST-CANCER (ABC), Annals of oncology, 9, 1998, pp. 115-115

Authors: CHARRIER S FERRIERE JP KWIATKOWSKI F CURE H VANPRAAGH I FEILLEL V ASSIER I BAY JO DAUPLAT J CHOLLET P

Citation: S. Charrier et al., OPTIMAL DURATION OF NEOADJUVANT CHEMOTHERAPY - 3 OR 4 VERSUS 6 CYCLESIN 3 SCHEMES FOR OPERABLE BREAST-CANCER, European journal of cancer, 33, 1997, pp. 360-360

Authors: CHOLLET P CHARRIER S BRAIN E CURE H VANPRAAGH I FEILLEL V DELATOUR M DAUPLAT J MISSET JL FERRIERE JP

Citation: P. Chollet et al., CLINICAL AND PATHOLOGICAL RESPONSE TO PRIMARY CHEMOTHERAPY IN OPERABLE BREAST-CANCER, European journal of cancer, 33(6), 1997, pp. 862-866

Authors: CURE H CHARRIER S FERRIERE JP VANPRAAGH I ASSIER I FEILLEL V DELATOUR M BAY JO ACHARD JL DAUPLAT J CHOLLET P

Citation: H. Cure et al., RESULTS OF 3 NEOADJUVANT CHEMOTHERAPY REG IMEN FOR OPERABLE BREAST-CANCER, Bulletin du cancer, 84(1), 1997, pp. 31-34

Authors: FLEURY J TORTOCHAUX J LEGROS M CURE H KWIATKOWSKI F FERRIERE JP TRAVADE P DIONET C GAILLARD G CHASSAGNE J BIGNON YJ VANPRAAGH I BELEMBAOGO E CHOLLET P PLAGNE R

Citation: J. Fleury et al., PRONOSTIC VALUE OF BETA-2-MICROGLOBULIN I N YOUNG-ADULTS WITH HODGKINS-DISEASE, Bulletin du cancer, 81(7), 1994, pp. 625-631